Ingemar Kihlström, born 1952
Chairman of the Board since 2006. Board member since 2003.
Associate Professor at Uppsala University. Ingemar Kihlström has worked with preclinical, clinical research and business development at Astra AB and Pharmacia AB for more than fifteen years. He has more than 10 years’ experience from the financial sector as an pharmaceutical analyst at companies such as Aros and ABG Sundal Collier. He is now an independent advisor to the biotech/medtech/pharmaceutical sector.
Other assignments
Chairman of the board of Recopharma AB, Innate Pharmaceuticals AB, Prolight Diagnostics AB and Acromed Invest AB, deputy chairman of the board of DiaGenic ASA, board member of Health Invest Partners AB, Medivir AB, Kezzler AS, Oxypharma AB and Respiratorius AB.
Holding in Artimplant
149 300 Series B stock units. No options in Artimplant.
Lennart Ribohn, born 1943
Board member since 2001.
Lennart Ribohn was employed by AB Electrolux 1963-2000, holding a number of leading positions including Group Controller, Chief Financial Officer and Senior Executive Vice President.
Other assignments
Chairman of the Board of Försäkrings AB Nordisk Garanti and a director of SEB Investment Management AB, Segulah Advisor AB and FPG Försäkringsaktiebolaget Pensionsgaranti. Board member of the Securities Council (Aktiemarknadsnämnden).
Holding in Artimplant
119 750 Series B stock units. No options in Artimplant.
Anna Malm Bernsten, born 1961
Board member since 2007. Deputy Board member in 2006.
Anna Malm Bernsten has vast management experience from the medical and pharmaceutical industry, former CEO of Carmeda and has held a number of senior positions in Assa Abloy, Medivir, Pharmacia, Baxter and Aerocrine AB. At present Chief Marketing Officer at GE Healthcare Life Sciences.
Other assignmentsBoard member of DiaGenic ASA, Fagerhult AB and Medivir AB.
Holding in Artimplant
No shares or options in Artimplant.
Wenche Rolfsen Sandsborg, born 1952
Board member since 2007.
PhD in pharmacy, Associate Professor at Uppsala University. Wenche Rolfsen Sandsborg has 16 years’ experience in leading positions within preclinical research and development at Pharmacia and she has been responsible for the early clinical organization for Quintiles Europe and president of Quintiles Scandinavia for a total of 11 years.
Other assignmentsChairman of the board of Aprea AB. Board member of Biovitrum AB, Industrifonden and Aker Biomarine AS.
Holding in Artimplant
20 000 Series B stock units. No options in Artimplant.
Mats Lindquist, born 1951
Board member since 2008.
Degrees from Uppsala University in psychology and economy. Employed by the Chamber of Commerce in the County of Uppsala. Formerly Vice President, Corporate Development for the contract research company Quintiles Transnational Corp. During the period 1998-2005, Mats Lindquist was President of Quintile AB´s operations in the Nordic region and the Baltic countries. Prior to this he held a number of different managerial positions within the global and local pharmaceutical industry.
Holding in Artimplant
30 000 Series B stock units. No options in Artimplant.
Auditors
Ernst Young AB
Responsible partner
Bertel Enlund, born 1950. Auditor since 2003.
Authorized Public Accountant
|
